Abciximab  (Synonyms: 阿昔单抗; C7E3)

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors^[1].

Fab G1 kappa

Chimeric

Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet α_IIbβ₃ integrin^[2].
Abciximab appears to have similar affinity for the α_IIbβ₃ and α_vβ₃ integrins and redistributes between them^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

143653-53-6

液体

Colorless to light yellow

阿昔单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Fab-G1-kappa

• 
  Loaded Abciximab on AHC2 biosensor, can bind Integrin alpha 2B beta 3 Protein, Human (HEK293, His, HY-P77716) with an affinity constant of 2.475E-09 M as determined in BLI assay.

• [1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.  [Content Brief]

  [2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38.  [Content Brief]